For decades, the medical world viewed Alzheimer's disease and cancer as two entirely separate conditions. But a recent study changed how medical science treats these ailments. A groundbreaking study from Boston Children's Hospital, published in the journal Cell, has uncovered an unexpected twist in how our cells age. According to a study published in ScienceDaily, researchers discovered that microglia—the immune cells residing inside the brain—accumulate mutations in specific cancer-driving genes. Instead of causing tumors, these genetic changes appear to contribute directly to the development of Alzheimer's disease.
Behind the Discovery
The study was led by Christopher Walsh, MD, PhD, chief of the Division of Genetics and Genomics at Boston Children's Hospital and an investigator of the Howard Hughes Medical Institute. Key collaborators included Alice Eunjung Lee, PhD, and August Yue Huang, PhD, who also work within the Division of Genetics and Genomics. All three scientists hold professor roles at Harvard Medical School and serve as associate members of the Broad Institute of MIT and Harvard. The team believes their findings could open up entirely new pathways for diagnosing and treating the disease.
Dementia, a progressive and debilitating neurological condition, has become a growing concern in healthcare systems worldwide. As the global population ages, there is an urgent need to develop effective strategies for early identification and intervention. In a promising development, a recent study published in the journal BMJ Mental Health introduced a groundbreaking dementia risk score that can identify individuals at risk of developing the disease within the next 14 years, starting in mid-life. This innovative tool, known as the UK Biobank Dementia Risk Score (UKBDRS), draws upon 11 predominantly modifiable risk factors, providing a robust framework for early detection and prevention efforts.
Re-evaluating the Connection to Cancer
According to the researchers, this newly discovered link could completely reshape our approach to finding treatments. "We find that to some extent, Alzheimer's disease is a little like cancer—driven by the same mutations that drive blood cancers like lymphoma and leukemia," said Walsh. "This is helpful because we have a lot of drugs to fight cancer and some of them might be useful therapeutically for Alzheimer's disease."
Finding Mutant Cells in Alzheimer's Brains
To map out this connection, the research team analyzed 149 cancer-driving genes in brain tissue samples from 190 people who had Alzheimer's disease, comparing them against samples from 121 healthy brains. The data showed that the Alzheimer's samples contained significantly more single-letter DNA changes than the healthy tissue. Interestingly, many of these genetic alterations repeatedly showed up in the exact same five cancer driver genes, meaning the microglia were picking up mutations in a highly specific set of genes.
The Brain's Local Defense Force
Under normal conditions, microglia serve as the brain's dedicated cleanup crew. Their main job is to clear away cellular debris and help eliminate cells that are infected, damaged, or dying. For a long time, scientists operated under the firm belief that microglia remain strictly confined to the brain. Unlike many other immune cells that constantly circulate through our bloodstream, microglia were not thought to cross the protective blood-brain barrier. Breast cancer showed the highest positivity rate of 34 per cent followed by gastrointestinal cancer (30 per cent), ovarian cancer (eight per cent) and prostate cancer (four per cent), according to the study.
Discovery in the Blood
Because the mutations identified in the microglia are the same ones commonly associated with blood cancers, the researchers decided to run an unexpected test. They looked for these identical genetic mutations in blood samples from the people with Alzheimer's disease. The team didn't actually expect to find anything. Instead, they were surprised to discover that the blood cells from those exact same Alzheimer's patients carried the identical cancer-associated mutations.
How the Disease Develops
Finding the same mutations in both the brain and blood suggested something entirely new to the researchers. "It was actually a really unexpected finding that suggests a totally new mechanism for Alzheimer's disease pathogenesis," said Huang. "The findings mean that the blood's immune cells with cancer mutations are likely getting into the brain and contributing to disease."
Weakened Barriers Fuel the Damage
The researchers propose a specific timeline for how this damage unfolds. They suggest that aging or physical injury can naturally weaken the blood-brain barrier over time, allowing mutant immune cells from the bloodstream to cross over into the brain. Once inside, these traveling blood cells transform into cells that behave like microglia. At the same time, the protein clumps that build up in an Alzheimer's brain trigger the surrounding microglia to rapidly multiply and respond.
Why Mutant Cells Take Over
In this high-stress environment, cells that possess any kind of biological advantage are much more likely to expand and dominate. This includes the newly arrived, microglia-like cells that carry the cancer-related mutations. According to the research team, these mutated cells create a far more inflammatory and damaging environment than healthy, normal microglia. As a direct result of this intense inflammation, nearby neurons are harmed and die, driving the steady progression of Alzheimer's.
Transforming the Treatment of Patients
This discovery could eventually give doctors a way to catch Alzheimer's risk much earlier than current methods allow. "Because it's hard to access brain tissue in a living patient, genetic screens using blood samples could be developed to test whether a person carries these mutations and has an increased risk of developing Alzheimer's disease," said Lee.
Confirming the Link
In a follow-up study posted as a preprint on bioRxiv, Huang and Lee uncovered even more evidence supporting this cellular connection. Their deeper analysis demonstrated that these cancer driver mutations detected in simple blood samples increased a person's Alzheimer's disease risk entirely independently of APOE4, which is currently the most well-established genetic risk factor for the disease.
